Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
KeyBanc Starts Castle Biosciences (CSTL) at Overweight
November 9, 2020 4:16 PM ESTKeyBanc initiates coverage on Castle Biosciences (NASDAQ: CSTL) with a Overweight rating and a price target of $70.00.
For an analyst ratings summary and ratings history on Castle Biosciences click here. For more ratings news on Castle Biosciences click here.
Shares of Castle Biosciences closed at $51.70 yesterday.
... More


